乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

ASH: Hematology

<乌鸦传媒>Dual Targeted CAR-T Yields 99% Response Rate in Pediatric ALL

Cytokine release syndrome developed in all patients, including grade 3/4 events in nearly half

<乌鸦传媒>New Standard for Newly Diagnosed Pediatric B-Cell Acute Lymphoblastic Leukemia

Blinatumomab consolidation reduced risk of relapse by 61% versus chemotherapy alone

<乌鸦传媒>Eltrombopag Improves Outcomes in Kids With Newly Diagnosed ITP

Drug may potentially "transform" approach to upfront treatment, investigator says

<乌鸦传媒>Hematocrit Stabilized in Polycythemia Vera Treated With Novel Hepcidin Mimetic

Rusfertide maintained hematocrit

<乌鸦传媒>Ibrutinib-Venetoclax Improves PFS in R/R Mantle Cell Lymphoma

Will results revive ibrutinib role in MCL following withdrawal of accelerated approval?

<乌鸦传媒>'Half-Matched' BMTs Effective in Severe Sickle Cell Disease

High survival rates observed in patients not normally suitable for transplant

<乌鸦传媒>Pomalidomide Cuts Severe Epistaxis in Genetic Bleeding Disorder

24 weeks of daily treatment significantly reduced recurrent nosebleeds in HHT trial

<乌鸦传媒>Four Drugs Top Three for Upfront Treatment of Multiple Myeloma

Adding anti-CD38 antibodies boosts response and PFS, but timing, sequencing, cost questioned

<乌鸦传媒>Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia

Investigational drug revumenib now under review at FDA for KMT2A-rearranged disease

<乌鸦传媒>Novel Monoclonal Antibody Reduces Bleeds in Hemophilia A and B

Marstacimab reduced the annualized bleeding rate versus on-demand, prophylactic treatments

<乌鸦传媒>Ruxolitinib Combinations Reduce Spleen Volume in Myelofibrosis

Combos with navitoclax or pelabresib led to more patients achieving reductions

<乌鸦传媒>Axatilimab Shows Efficacy in Recurrent/Refractory GVHD

Highest overall response rate and least toxicity seen with lowest dose

<乌鸦传媒>MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia

No advantage for MRD-negative patients in first remission after induction, regardless of FLT3 ITD

<乌鸦传媒>ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remission

Better 2-year PFS, OS, but not applicable to primary refractory disease

<乌鸦传媒>Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients

Time-limited approach based on MRD response outperforms FCR, but U.S. applicability unclear

<乌鸦传媒>Emicizumab Safe, Effective, in Infants With Hemophilia A

More than half of children in study had no treated bleeds at follow-up of more than 100 weeks

<乌鸦传媒>Lovo-Cel 'Life-Changing, Transformative' in Sickle Cell Disease

Near complete resolution of pain events in patients, including adolescents

<乌鸦传媒>Benefits of Myeloma Regimens in the Real World Fall Well Short of Trials

Survival 75% worse compared with outcomes seen in registrational studies

<乌鸦传媒>Completely Oral Regimen Effective, Feasible in APL

97% of patients alive and relapse-free at 3 years

<乌鸦传媒>Anti-PD-1 Drugs Impress as Frontline Therapy for Early, Unfavorable Hodgkin's

3-year PFS of 99%, OS of 100% with nivolumab-chemo, high response rate with pembrolizumab

<乌鸦传媒>New Regimen for GvHD Prophylaxis in Well-Matched Reduced-Intensity Allo-HCT

Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk

<乌鸦传媒>'Practice-Changing' Results With Zanubrutinib Versus Ibrutinib in CLL/SLL

Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease

<乌鸦传媒>C3 Pathway Inhibitor May Change Practice for Paroxysmal Nocturnal Hemoglobinuria

Iptacopan improved hemoglobin without transfusion versus current standard of care

<乌鸦传媒>High-Dose Chemo, ASCT Improves Survival in Primary CNS Lymphoma

European trial is "practice-changing as of today," says U.S. expert

<乌鸦传媒>Prolonged Responses in DLBCL Spark Talk of a Cure With Bispecific Antibody

Most complete responses lasted 24 months or longer after limited-duration glofitamab

<乌鸦传媒>Blinatumomab-Chemo Consolidation a 'New Standard' in MRD-Negative B-ALL

Phase III study showed 58% reduction in the risk of death versus chemo alone

<乌鸦传媒>Pediatric Hodgkin Lymphoma Survivors Experience Accelerated Epigenetic Aging

Data from St. Jude cohort show higher rates of neurocognitive impairment

<乌鸦传媒>Heparin Fails to Stop Miscarriages in Women With Inherited Thrombophilia

No difference in live birth rates with or without blood thinner

<乌鸦传媒>Durable Platelet Response in Immune Thrombocytopenia With Efgartigimod

Glycoprotein receptor inhibitor produces four times as many responses as placebo

<乌鸦传媒>Black Patients Less Likely to Get Advanced Treatments for PE

Also less likely for patients on Medicare and Medicaid

<乌鸦传媒>AML Study Suggests Intensive Chemo Unnecessary Before Allo-HCT

Similar outcomes if patients went directly to transplant or received intensive salvage first

<乌鸦传媒>Talquetamab Offers New Hope in Relapsed/Refractory Multiple Myeloma

Bispecific antibody achieves "incredible" response rates over 70% in heavily pretreated patients

<乌鸦传媒>Ibrutinib Makes Its Case for First-Line Treatment in Mantle Cell Lymphoma

Standard-of-care autologous transplant fails to prove superior to BTK inhibitor alone

<乌鸦传媒>Rigid In-Hospital Diet Offers No Advantage in Patients After HSCT

"We should eliminate these silly neutropenic diets," expert says

<乌鸦传媒>Targeted Agent Improves Survival in FLT3-Positive Acute Myeloid Leukemia

OS, EFS improved versus historical controls with addition of midostaurin to chemotherapy

<乌鸦传媒>Another Study Reinforces Chemo-Free Therapy for Newly Diagnosed CLL

Ibrutinib-rituximab extends PFS versus chemoimmunotherapy, especially in unmutated disease

<乌鸦传媒>Less Is More: Rituximab Retreatment Tops Maintenance for Follicular Lymphoma

Updated analysis confirms advantages of less aggressive approach to low-burden disease

<乌鸦传媒>Gene Therapy Resolves Severe Pain Events in Sickle Cell Disease

LentiGlobin also normalized hemoglobin and reduced hemolysis markers

<乌鸦传媒>Can Dasatinib Dose Be Halved in Low-Risk CML?

Lower dose associated with improved tolerability, similar responses in propensity score analysis

<乌鸦传媒>CAR T-Cell Win Streak Stopped by Negative Trial in Aggressive LBCL

Patients, trial design, logistics among possible explanations for lack of EFS benefit

1